Birchtech vs Nephros
BCHT and NEPH side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCHT and NEPH compare
Nephros is the larger company, worth 1.2 times as much as Birchtech ($33.3M against $28.9M).
Nephros grew revenue faster over the last twelve months (20.4% versus 11.0% for Birchtech).
Nephros scores higher on the StockData Score (13 against 7 for Birchtech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCHT | NEPH |
|---|---|---|
| Size and price | ||
| Market cap | $28.9M | $33.3M |
| Share price | $1.10 | $3.07 |
| Change, 1 year | −68.6% | −28.4% |
| Change, 5 years | −71.8% | −58.6% |
| Beta (5Y) | 0.62 | 0.58 |
| Employees | 20 | 36 |
| StockData Score | ||
| Total score | 7 | 13 (better) |
| Valuation score | 2 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.1× |
| P/S | 1.5× (better) | 1.5× |
| P/B | 3.5× | – |
| EV/EBITDA | – | 14.8× |
| FCF yield | −13.3% | – |
| Fair value | $1.97 | $4.25 |
| Margin of safety | 44.3% (better) | 27.7% |
| Growth | ||
| Revenue growth (TTM) | 11.0% | 20.4% (better) |
| Revenue growth, 5Y average | 16.7% | 17.0% (better) |
| Net income growth (TTM) | – | 29.0% |
| EPS growth (TTM) | – | 38.5% |
| Profitability | ||
| Gross margin | 39.7% | 60.5% (better) |
| Operating margin | −17.1% | 8.5% (better) |
| Net margin | – | 8.9% |
| FCF margin | −20.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −240.4× | – |
| Current ratio | 1.42 | 5.50 (better) |
| Altman Z-score | −3.52 | −3.01 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 17.3% | 48.9% |
| Held by insiders | 65.4% | 9.2% |
| Insider net buying, 12 months | $750K | – |
| Short interest, % of float | 0.38% | 0.12% |
Go deeper
- BCHT stock overview
- BCHT income statement
- BCHT valuation and score
- NEPH stock overview
- NEPH income statement
- NEPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.